Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + Tislelizumab in Recurrent Cervical Cancer
NCT06063018Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Cervical Cancer (CC), sponsored by Peking Union Medical College Hospital. Started Aug 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06063018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063018.